[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-anxiety-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-anxiety-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,51,85,109,134,166,191,244,279,308,331,353,376,409,436],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100644239","mobile-app-based-yoga-and-meditation-in-rheumatoid-arthritis-100644239",false,"NCT07666594","Mobile App-Based Yoga and Meditation in Rheumatoid Arthritis","Effectiveness of a Mobile Application-Based Yoga and Meditation Program in Patients With Rheumatoid Arthritis: A Single-Blind Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years.\n* Diagnosed with Rheumatoid Arthritis (RA) by a rheumatologist.\n* Disease in a stable phase (remission or low disease activity).\n* Access to a smartphone or tablet and sufficient proficiency in using mobile applications.\n* Cognitive sufficiency to provide written and verbal informed consent in Turkish.\n\nExclusion Criteria:\n\n* Presence of acute RA flare-ups.\n* Severe psychiatric diagnoses (e.g., psychosis, bipolar disorder, or severe major depression).\n* Severe cognitive impairment or dementia.\n* Pregnancy.\n* Regular practice of meditation or mindfulness within the last 6 months.\n* Participation in any other stress management program within the last 3 months.\n* Receipt of mental health services within the last 6 months.","ALL","18 Years","65 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this single-blind, randomized controlled trial is to evaluate the clinical effectiveness and short-term economic impact of a mobile application-based, personalized yoga and meditation program in adult patients with Rheumatoid Arthritis (RA).\n\nThe main questions it aims to answer are:\n\nDoes an 8-week digital yoga and meditation intervention reduce anxiety and improve other clinical\u002Fpsychological outcomes (such as depression, pulmonary function, reaction time, quality of life, and stress) compared to standard medical care? Does this digital intervention reduce short-term healthcare utilization and associated direct medical costs?\n\nResearchers will compare the Mobile App Group (receiving personalized yoga and meditation via the Meditopia app) to a Control Group (receiving usual medical care) to evaluate the effectiveness and cost-efficiency of the intervention.\n\nParticipants in the experimental group will:\n\nUse a mobile application to practice 15-30 minutes of yoga and 15-30 minutes of meditation daily, at least 4 days a week over an 8-week period.\n\nComplete clinical, psychometric, and economic assessments at baseline, week 4, and week 8.",[27,28,29,30],"Rheumatoid Arthritis (RA)","Anxiety","Depression Anxiety Disorder","Mobile Health Technology (mHealth)",[32,33,34,35,36,37],"Rheumatoid Arthritis","Yoga","Mobile Health (mHealth)","Meditation","Cost Analysis","Psychological Stress","NOT_YET_RECRUITING","2026-06-18",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":21},"2026-06",{"date":46,"type":21},"2027-06",{"name":48,"class":49},"Tugba Civi Karaaslan","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100639687","group-based-act-for-psychological-distress-of-young-people-100639687","NCT07617467","Group-based ACT for Psychological Distress of Young People","ACT-YOUNG","Inclusion Criteria:\n\n* Score on DASS-21 depression scale ≤ 14\n\nExclusion Criteria:\n\n* Psychosis","16 Years","25 Years",{"count":61,"type":21},212,[24],"This clinical study investigates the effectiveness of two psychological treatment formats for young people aged 16-25 with symptoms of depression, anxiety, stress, or interpersonal difficulties. The study compares group-based Acceptance and Commitment Therapy (ACT) with treatment as usual (TAU), most frequent that would be individual psychotherapy, both of which are established treatment approaches.\n\nThe study uses a randomized controlled design (RCT), in which participants are randomly assigned to one of the two treatment conditions. This allows for a systematic comparison of treatment outcomes between ACT delivered in a group format and standard individual therapy.\n\nThe ACT group intervention consists of a structured program in which participants meet regularly over a defined treatment period. The treatment focuses on processes such as psychological flexibility, acceptance of internal experiences, and engagement in actions aligned with personal values.\n\nThe individual therapy condition consists of one-to-one sessions with a clinician, following standard therapeutic practice. Treatment content and duration are tailored to the participant's clinical presentation and therapeutic needs.\n\nOutcome measures include standardized assessments of mental health symptoms, functioning, and psychological processes. These assessments are conducted at baseline, during the treatment period, at post-treatment, and at follow-up time points. Data collected from these measures will be used to evaluate changes over time and differences between the two treatment conditions.\n\nThe primary aim of the study is to determine whether group-based ACT is as effective as, or more effective than, individual psychotherapy for young people receiving mental health services. The results are expected to contribute to improved knowledge about treatment options for this age group and inform future clinical practice.",[65,29,28,66],"Depression - Major Depressive Disorder","Anxiety Depression",[68,69,70,71,72],"depression","Acceptance and Commitment Therapy","anxiety","anxiety depression","adolescents","RECRUITING","2026-05-22",{"date":76,"type":42},"2026-06-01",{"date":78,"type":42},"2026-03-09",{"date":80,"type":21},"2028-12-31",{"name":82,"class":83},"Sorlandet Hospital HF","OTHER_GOV",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100634813","phenotypic-exploration-during-sensory-stimulation-in-an-acoustic-chamber-100634813","NCT07544563","Phenotypic Exploration During Sensory Stimulation in an Acoustic Chamber","Exploration phénotypique en Contexte de Stimulations Sensorielles en Chambre Acoustique","EMO-INTRA","Inclusion Criteria:\n\n* For patients : epilepsy\n* For healthy volunteers: age \\> 18 yo\n\nExclusion Criteria:\n\n* For patients and healthy volonteers : Deafness\n* For healthy volunteers : History of neurological conditions (including stroke, coma, epilepsy, neuro-inflammatory or neurodegenerative disease) or diagnosed cognitive impairment",true,{"count":95,"type":21},320,"OBSERVATIONAL","An observational behavioural and neurophysiological study of the effects of controlled sensory stimulation (such as music, for example) on brain function",[99,28,29],"Epilepsy","2026-04-15",{"date":102,"type":42},"2026-04-22",{"date":104,"type":42},"2025-12-02",{"date":106,"type":21},"2035-12-02",{"name":108,"class":49},"Centre Hospitalier St Anne",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":50},"100619476","cost-effectiveness-and-implementation-of-a-transdiagnostic-internet-based-intervention-for-emotional-disorders-in-community-care-100619476","NCT07345117","Cost-effectiveness and Implementation of a Transdiagnostic Internet-based Intervention for Emotional Disorders in Community Care.","From Research to Clinical Practice: Implementation of an Internet-based Transdiagnostic Treatment Program for Emotional Disorders in Primary Care (TREAT-ED)","TREAT-ED","Patient Inclusion Criteria:\n\n* Over 18 years of age.\n* Meet the diagnostic criteria for an anxiety or depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n* Understand and read Spanish or Catalan.\n* Have access to the Internet and an email address\n* Give informed consent.\n\nPatient Exclusion Criteria:\n\n* Diagnosis of schizophrenia, bipolar disorder, or alcohol or substance dependence.\n* High risk of suicide.\n* Presence of a medical condition that prevents psychological treatment.\n* Receiving other psychological treatment (other than TAU or the online program) during the study.\n* For participants in the online treatment condition with pharmacological treatment, this must be stabilized (doses cannot be changed or increased during the study, only reduced).\n\nInclusion Criteria for mental health Professionals:\n\n* They work at centers participating in the study.\n* They agree to participate in the study.\n* They sign an informed consent form.",{"count":118,"type":21},200,[24],"Emotional disorders (ED) are one of the leading causes of disability. They are highly prevalent and have an impact on quality of life. Addressing them places an overload on the National Health System (NHS), generating waiting lists and limiting appropriate care. The need for cost-effective solutions has led to the consideration of the transdiagnostic approach and the use of digital solutions. Both perspectives have demonstrated efficacy in a large number of randomized clinical trials. As a result, investment in digital health interventions is on the rise to improve access to care in overburdened healthcare systems. However, their integration and implementation in health systems remains limited. Implementation Science emerges to facilitate the integration of interventions into clinical practice through specific strategies that overcome barriers and optimize their sustainability. The objective of this project is to examine the effectiveness, economic costs and feasibility of implementing an online psychological treatment program for emotional disorders in mental health services. The Mutua and UJI teams have already carried out the transfer of the online program. In order to facilitate the adoption and sustainability of this program and that it can be used by mental health professionals in daily practice, a hybrid design 1 study will be carried out in which not only the efficacy but also the possibility of adoption and the analysis of economic costs in comparison with the usual treatment will be evaluated.",[122,29,123,124],"Emotional Disorders","Depression Disorders","Anxiety Disorders","2026-03-17",{"date":127,"type":42},"2026-03-18",{"date":129,"type":21},"2026-04-01",{"date":131,"type":21},"2029-01-01",{"name":133,"class":49},"Universitat Jaume I",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":145,"conditions":146,"keywords":151,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":50},"100614501","evolution-of-insomnia-during-the-first-year-in-patients-newly-diagnosed-with-cancer-100614501","NCT07280416","Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer","Evolution of Insomnia During the First Year in Patients Newly Diagnosed With Cancer: a Longitudinal Study and Analysis of Associated Factors.","INDICA","Inclusion Criteria:\n\n* Confirmed diagnosis of metastatic or non-metastatic cancer,\n* Cancer treated with intravenous chemotherapy and\u002For immunotherapy administered intravenously or subcutaneously,\n* Age ≥ 18 years,\n* Ability to read and understand French,\n* Patient covered by a social security system,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* SCI questionnaire score \\\u003C16\n* Diagnosed or controlled sleep disorders\n* Presence of severe cognitive disorders (e.g., Alzheimer's disease) or major psychiatric disorders (e.g., psychosis), as noted in the medical record, observed at recruitment, or reported by the patient\n* Patient in an emergency situation, or subject to a legal protection measure (guardianship, curatorship, or judicial protection) and unable to provide consent","80 Years",{"count":144,"type":21},260,"The diagnosis of cancer can be a major trigger for new sleep problems, especially insomnia, in people who did not have sleep issues before. Insomnia may appear early in the care pathway and can continue over time, often interacting with other physical or emotional symptoms.\n\nThe main goal of this preliminary study is to describe how insomnia develops during the first months after a cancer diagnosis in patients who had no sleep problems at the time of diagnosis. This will be done through regular follow-up over time.\n\nA secondary aim is to identify the factors that may contribute to the onset or persistence of insomnia, such as the cancer treatments patients receive, as well as any medical or non-medical therapies used to manage sleep difficulties.\n\nThe study will also look at whether patients who develop sleep problems are referred to psychologists trained in specific therapies for insomnia, and how well they follow and adhere to these treatments.",[147,148,149,29,150],"Cancer","Insomnia","Pain","Quality of Life",[152,153,154,155,156],"cancer","insomnia","pain","Depresion Anxiety disorder","longitudinal","2026-02-09",{"date":159,"type":42},"2026-02-11",{"date":161,"type":42},"2025-12-16",{"date":163,"type":21},"2028-11-01",{"name":165,"class":49},"Centre Hospitalier Emile Roux",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":4},"100623834","efficacy-and-safety-evaluation-of-remote-ischemic-adaptation--intermittent-pressure-stimulation--in-the-treatment-of-insomnia-after-stroke-100623834","NCT07401784","Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of Insomnia After Stroke","Inclusion Criteria:\n\n* Age 18-80 years old ;\n* In line with the diagnostic criteria of ischemic stroke, with reference to the ' Chinese guidelines for the diagnosis and treatment of acute ischemic stroke ' diagnosed ischemic stroke ;\n* Despite adequate sleep opportunities, patients still have difficulty in falling asleep or maintaining sleep, staying asleep at least 3 times a week for at least 3 months, which leads to pain or impaired daytime function.\n* PSQI score ≥ 6 and ISI score ≥ 8 ;\n* All research contents have been understood and informed consent has been signed.\n\nExclusion Criteria:\n\n* Insomnia before stroke ;\n* Patients with mental disorders, bipolar disorder or depression, generalized anxiety disorder and other mental disorders ;\n* Patients were pregnant or lactating women ;\n* Other reasons identified by the researchers are not suitable for patients ;",{"count":173,"type":21},40,[24],"The incidence of post-stroke depression is high, which will affect the rehabilitation of neurological function, damage cognitive function, and increase the risk of subsequent stroke recurrence. The guidelines recommend that in addition to antiplatelet, blood pressure control, lipid-lowering and other treatments, secondary prevention of post-stroke depression should also be strengthened. Moreover, after the occurrence of post-stroke depression, methods such as medication and psychotherapy have their own limitations, such as potential adverse drug reactions and limited psychotherapy. Therefore, it is necessary to pay attention to the prevention of post-stroke depression.\n\nThe remote ischemic adaptation therapy applied in our study is a safe, non-invasive and convenient physical therapy. By transiently and repeatedly applying ischemia-reperfusion stimulation to both upper arms, it induces a systemic protective response, improves the brain 's tolerance to ischemia and hypoxia, and exerts a protective effect on multiple organs such as the brain and heart. The RIC therapeutic instrument has been national patented and has been maturely applied to the prevention and treatment of acute cerebral infarction, which can promote the rehabilitation of neurological function. In addition, it also has certain curative effect in the treatment of cerebrovascular stenosis, refractory hypertension, depression, insomnia, anxiety and so on.",[177,29,178],"Cerebral Apoplexy","Cerebrovascular Disease",[180,181,29,178],"Remote ischemic adaptation technology","cerebral apoplexy","2026-02-03",{"date":184,"type":42},"2026-02-10",{"date":186,"type":21},"2026-01-27",{"date":188,"type":21},"2027-12-30",{"name":190,"class":49},"Second Affiliated Hospital of Nanchang University",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":198,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":200,"conditions":201,"keywords":219,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100609246","precision-subclassification-of-mental-health-in-diabetes-digital-twins-for-precision-mental-health-to-track-subgroups-100609246","NCT07212075","Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups","TwinPeaks","Inclusion Criteria:\n\n* 18 to 80 years of age\n* Diagnosis of type 1 diabetes or type 2 diabetes or other specific type of diabetes\n* Diabetes duration ≥ 1 year\n* Sufficient German language skills\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to consent\n* Significant cognitive impairment (e.g. dementia)\n* Severe disorder or condition impacting the person's ability to participate in the study or likely to confound results (e.g. treated cancer, heart disease ≥ NYHA III, schizophrenia\u002Fpsychotic disorder)\n* Terminal illness\n* Being bedridden",{"count":199,"type":21},1809,"Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes. Evidence supports a complex network between psychosocial factors and glycaemic control that can be highly variable between persons. It is assumed that subgroups exist that show different trajectories of glycaemia and mental health.\n\nBelonging to a particular subgroup may be linked with a higher risk of developing mental health problems compared to others. This suggests that it is possible to treat individuals in different subgroups in a manner that optimizes their treatment and can improve health outcomes. Accurate characterisation can inform more individualized care. This calls for a more personalised approach considering the idiosyncrasies of different subgroups.\n\nOver 3 years, the investigators have established the basis of a precision mental health approach for diabetes using n-of-1 analyses. By utilizing combined ecological momentary assessment (EMA: repeated daily sampling of psychosocial factors in everyday life) and continuous glucose monitoring (CGM), intensive longitudinal data per person could be collected. This enables the analysis of individual associations between glycaemic parameters and psychosocial variables and identification of individual sources of diabetes distress in each person.\n\nThe objective of the present study is to use of the n-of-1 approach to identify subgroups of PWD who share common characteristics in the associations between glucose and psychosocial variables. The identified subgroups shall be used to develop a digital twin for precision mental health in diabetes. The digital twin serves as representation of a real person, allowing to make simulations and predictions of the course of mental health and glycaemia. These predictions can inform diabetes care and lead to more precise, personalised treatment decisions.\n\nTo achieve this, a longitudinal panel including over 1,400 PWD who continuously complete EMA and questionnaire surveys and measure glucose levels using CGM was developed. Over 1000 clinical interviews to diagnose mental disorders have been conducted to identify major mental health conditions and map mental outcomes. To identify subgroups and develop the digital twin, the sampling will be expanded aiming at a total of 1,809 PWD. Incidence and remission of mental disorders will be determined via repeated interviews.\n\nThe complex networks between clinical, metabolic, and psychosocial data will be analysed using machine learning, leading to new insights with the potential to shape future guidelines. These results will be used by the digital twin to predict courses of glycaemic control and mental health, translating the individual evidence into direct treatment suggestions.",[202,203,204,205,206,207,65,29,208,123,209,210,211,212,213,214,215,216,217,218],"Diabetes (DM)","Diabete Mellitus","Diabete Type 1","Diabete Type 2","Diabetes Distress","Diabetes Complications","Depression Bipolar","Anxiety Disorder (Panic Disorder or GAD)","Anxiety Disorder NOS","Eating Disorder Binge","Anorexia Nervosa","Bulimia Nervosa","Eating Disorder Not Otherwise Specified","Depressed Mood","Anxiety Symptoms","Disordered Eating Behaviors","Fear of Hypoglycemia",[220,221,222,223,224,225,226,227,228,229,230,231,232,28,233,206,196],"Digital Twin","Precision Medicine","Precision Mental Health","Subclassification","Trajectories","Subtypes","Person-reported Outcomes (PRO)","Ecological Momentary Assessment (EMA)","Continuous Glucose Monitoring (CGM)","People with Diabetes (PWD)","Diabetes Mellitus","HbA1c","Depression","Eating disorder","2025-11-27",{"date":236,"type":42},"2025-12-04",{"date":238,"type":42},"2025-01-01",{"date":240,"type":21},"2027-12-31",{"name":242,"class":49},"Forschungsinstitut der Diabetes Akademie Mergentheim",3,{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":262,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":50},"100611344","culturally-adapted-dialectical-behavior-therapy-for-low-middle-income-countries-100611344","NCT07239362","CULTURALLY ADAPTED DIALECTICAL BEHAVIOR THERAPY FOR LOW-MIDDLE-INCOME COUNTRIES","Culturally Adapted Dialectical Behavior Therapy (DBT) for Mental Health in LMICs: A Randomized Controlled Trial (RCT)","Inclusion Criteria:\n\n* Adults aged 18-45 years\n* Adults who are diagnosed with or have significant traits of borderline personality disorder (BPD)\n* Adults who are willing to provide written informed consent\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidity (e.g., active psychosis, substance use, etc.)\n* Acute medical conditions interfering with participation\n* Lack of basic reading and writing, or any learning disability","45 Years",{"count":253,"type":21},220,[24],"The study aims to assess the efficacy of culturally adapted dialectical behaviour therapy (DBT) for addressing emotional dysregulation in a low- and middle-income country, as well as to evaluate the impact of DBT on secondary outcomes such as borderline personality traits, self-harm or suicide, depression, anxiety, and individuals' functioning and disability.\n\nThrough a rigorous Randomised Controlled Trial (RCT), the research seeks to assess how cultural adaptations of dialectical behaviour therapy improve its applicability, engagement, and outcomes in diverse socio-cultural settings, contributing to more accessible and effective mental health interventions in resource-limited regions.",[257,258,259,260,261,29],"Borderline Personality Disorder (BPD)","Dialectical Behavior Therapy","Emotional Dysregulation","Self Harm","Suicidal and Self-injurious Behavior",[263,264,265,266,267,268,269],"BPD","DBT","Self harm","Suicide","Borderline personality","Dialectical behavior therapy","Emotional dysregulation","2025-11-22",{"date":272,"type":42},"2025-11-28",{"date":274,"type":21},"2025-11-20",{"date":276,"type":21},"2026-07-31",{"name":278,"class":49},"Pakistan Association of Cognitive Therapists",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":93,"sex":16,"minAge":287,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":50},"100609798","mental-health-cpr-for-cancer-survivors-100609798","NCT07219264","Mental Health CPR for Cancer Survivors","Mental Health CPR: Transforming Cancer Survivors' Mental Health With Community Participatory Reach","MH-CPR CaS","The study will include adults of all ages representing individuals across all the adulthood stage. The minimum age requirement is 21, which is the legal age of majority in Puerto Rico.\n\nInclusion Criteria:\n\n* Eligibility Criteria for Sub-Aim 1a. The eligibility criteria for the qualitative interviews will be 1: Participants over 21 years old, 2: through their role or status, represent any of the following community sectors: cancer care community organization representatives, clinical care providers of cancer patients and survivors, and cancer health educators; 3: self-identified as a Latino\u002FHispanic; 4: be able to complete an interview.\n* Eligibility Criteria for Aim 2. Community Forums stakeholders eligibility criteria. The community stakeholders inclusion criteria for the community forum are 1: Participants over 21 years old, 2: through their role or status, represent any of the following community sectors: cancer patients\u002Fsurvivors, cancer patients\u002Fsurvivors identified family caregiver, healthcare providers, cancer supportive care organizations, and advocacy groups, 3: self-identified as a Latino\u002FHispanic, 4: be able to attend the community forums.\n* Community Leaders Eligibility Criteria for CMHW training. The inclusion criteria for the community leaders to be trained as CMHW are 1: Participants over 21 years of age, 2: living in a limited resource community in southern Puerto Rico, 3: self-identified as a Latino\u002FHispanic, and 4: be able to provide support to H-CAPS through their role as CMHW.\n* Communities Eligibility Criteria. Community municipalities included from the southern health region of Puerto Rico are: Ponce, Arroyo, Coamo, Yauco, Salinas, Guanica, Guayanilla, Juana Diaz, Adjuntas, Guayama, Patillas, Santa Isabel, Penuelas and Villalba. These municipalities were chosen because they represent the catchment area of Ponce Health Sciences University.\n\nAlso, they are comprised of mostly rural areas (south-central region of Puerto Rico) and present a higher incidence of cancer (south region) and cancer mortality (south-central region) compared to other Puerto Rican Health regions.\n\n* Intervention eligibility criteria. The eligibility criteria for the community intervention are 1: Participants over 21 years old, 2: living in any of the municipalities of the southern health region of Puerto Rico and within a limited resource community according to the CDC SVI, 3: self-identified as a Latino\u002FHispanic, and 4: have had a cancer diagnosis during their adulthood.\n\nExclusion Criteria:\n\n* Participants residing outside the catchment area.","21 Years","99 Years",{"count":290,"type":21},1260,[24],"This is a parallel, two-arm interventional study comparing the Mental Health CPR behavioral intervention to standard community health education. The goal of this clinical trial is to learn if Mental Health CPR program, a culturally and linguistically adapted behavioral intervention, helps improve emotional well-being and access to mental health services among Hispanic\u002FLatino cancer survivors in Puerto Rico.\n\nThe main questions it aims to answer are:\n\n* Does Mental Health CPR help more people complete psychological distress screening?\n* Does it help more participants connect with psycho-oncology services? Researchers will compare the Mental Health CPR program to standard community health education to determine whether it improves emotional well-being, enhances communication between patients and caregivers, reduces negative attitudes toward mental health care, and lowers emotional distress levels.\n\nParticipants will:\n\n* Attend community sessions led by trained Community Mental Health Workers (CMHWs)\n* Receive printed materials and educational resources\n* Take part in brief follow-ups over about 36 weeks",[294,295,29],"Mental Health Care","Mental Health",[295,297,232,28],"Distress","2025-10-17",{"date":300,"type":42},"2025-10-21",{"date":302,"type":42},"2025-09-26",{"date":304,"type":21},"2028-08-31",{"name":306,"class":307},"Ponce Medical School Foundation, Inc.","INDUSTRY",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":50},"100574882","phase-2-effect-of-probiotics-psychobiotics-on-depression-and-metabolic-syndrome-in-saudi-arabia-100574882","NCT06765057","Effect of Probiotics \"Psychobiotics\" on Depression and Metabolic Syndrome in Saudi Arabia","Effect of Probiotics \"Psychobiotics\" on Depression in Adults With Pre-Metabolic Syndrome and Metabolic Syndrome in Riyadh City","Inclusion Criteria:\n\n* Major Depression Disorder (MDD) patients on antidepressants for at least 4 weeks or more.\n* MDD patients with pre-metabolic syndrome (at least 2 of the MetS components) and metabolic syndrome (at least 3 of the following components: central obesity with WC for men ≥ 94 centimeters while for women ≥ 80 centimeter, increased FPG ≥ 100 mg\u002Fdl, increased BP to ≥ 130 \u002F ≥ 85 mmHg, increased TGs equal or above 150 mg \u002F dl, increased HDL cholesterol for men to \\\u003C 40 mg \u002F dl while for women \\\u003C 50 mg \u002F dl) (IDF., 2006).\n* MDD patients with other comorbid diseases such as anxiety.\n\nExclusion Criteria:\n\n* Patients using any other supplements to improve mood.\n* Patients using pre\u002Fpro\u002Fsymbiotics supplement or antibiotics during the last 3 weeks before the intervention.\n* Patients with chronic diseases (cardiac, renal, or hepatic diseases)\n* Patients with gastro intestinal diseases (Crohn's disease, ulcerative colitis).\n* Patients with infectious diseases (HIV\u002FAIDS).\n* Cancer patients or those undergoing chemotherapy.\n* Patients with food allergies such as gluten intolerance or lactose intolerance.\n* Pregnant and breastfeeding women.\n* Patients with modified antidepressant dose during interventional period or receiving psychotherapy during the intervention.\n* Patients with thyroid disorder.\n* Patients following a diet to lose weight during the intervention.\n* Diabetic patients who are insulin-dependent.\n* patients receiving injections or medications to lose weight (Ozempic, Mounjaro …etc) either 3 weeks before or during the intervention.\n* Patients using plasma-lipid lowering drug for less than 1 month before the intervention.\n* Patients with substance abuse including alcohol addiction.",{"count":316,"type":21},60,[318,319],"PHASE2","PHASE3","The goal of this clinical trial is to assess the effect of commercial multi-strains psychobiotics supplementation as an ad-on therapy on depressive symptoms and metabolic syndrome components (HDL-C, FPG, TGs, WC, BP) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The second goal is to explore the effect of commercial multi-strains psychobiotics supplementation on the anthropometric measurement (weight, body mass index (BMI)) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The main questions they aim to answer are:\n\n* Will commercial multi-strains psychobiotics supplementation help to ease depressive symptoms as an ad-on therapy in patients with pre-metabolic syndrome and metabolic syndrome?\n* Will commercial multi-strains psychobiotics supplementation improve anthropometric measurements and metabolic syndrome components (WC, FPG, BP, TGs, HDL-C) in depressed patients? Researchers will compare psychobiotics to a placebo (a look-alike substance that contains no drug) to see if psychobiotics work to improve depression and metabolic syndrome components.\n\nParticipants will:\n\n* Be examined for depression, anxiety, and metabolic syndrome components (waist circumference, diabetes, blood pressure, triglycerides, and high-density lipoprotein).\n* Be asked to conduct laboratory tests to determine the inclusion and exclusion criteria.\n* Be given probiotics\u002F placebo to consume every day for 3 months (12 weeks).\n* Repeat the examination and laboratory tests to determine the results.\n* Be followed up weekly for adverse events and to insure their compliance with the study instructions.\n* Be followed up after 4 weeks as an end-visit and will conduct the examination and the laboratory blood tests.",[29],"2025-09-16",{"date":324,"type":42},"2025-09-22",{"date":326,"type":42},"2025-03-02",{"date":328,"type":21},"2027-01-30",{"name":330,"class":83},"Roaa Ahmed Alkreadees",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":93,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":4},"100604308","digital-silence-and-mental-health-100604308","NCT07147829","Digital Silence and Mental Health","Digital Silence and Mental Health: The Effects of a Digital Detox Intervention on Depression, Stress, Anxiety, Sleep Quality, and Emotion Regulation in Young Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Owning a smartphone\n* Using social media for ≥ 8 hours per day\n* Not having a diagnosis related to anxiety, depression, stress, sleep, or emotional regulation\n* Living in an environment with internet access\n* Providing voluntary informed consent\n\nExclusion Criteria:\n\n* Having a history of psychiatric diagnosis\n* Currently using psychiatric medication\n* Having received psychological counseling in the past 6 months\n* Having a diagnosis of sleep disorder",{"count":339,"type":21},100,[24],"Social media use has been linked to negative mental health outcomes, including increased anxiety, depression, stress, poor sleep quality, and difficulties in emotion regulation. Digital detox interventions, which involve reducing or temporarily eliminating digital engagement, have emerged as a strategy to mitigate these effects. However, current evidence regarding their effectiveness is mixed and limited by short-term follow-ups and methodological variability. This study aims to examine the impact of a digital detox intervention on depression, anxiety, stress, sleep quality, and emotion regulation in young adults.",[29,343],"Sleep Quality","2025-09-15",{"date":346,"type":42},"2025-09-18",{"date":348,"type":21},"2025-10-01",{"date":350,"type":21},"2026-01-30",{"name":352,"class":49},"Ataturk University",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":50},"100594910","effect-of-exercise-on-tapering-antipsychotics-in-patients-with-psycho-cardiological-diseaseextra-study-100594910","NCT07025590","Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease: a Multicenter, Randomized Controlled, Non-inferior Clinical Study","Inclusion Criteria:\n\n1. Diagnosed with depression\u002Fanxiety;\n2. Continued use of SSris and SNris for six months prior to study start;\n3. Aged between 18 and 70;\n4. Confirmed cardiovascular disease (such as chronic stable coronary heart disease, heart failure, cardiomyopathy, arrhythmia, valvular heart disease, cardiac surgery, cardiac intervention, ischemia with non-obstructive coronary artery disease, etc.);\n5. The patients voluntarily participated in the study, signed a written informed consent, and were willing to cooperate with the follow-up.\n\nExclusion Criteria:\n\n1. currently has mania or hypomania, or a history of bipolar disorder and any mental disorders (current and previous);\n2. organic brain injury, etc., or serious non-cardiovascular system diseases (such as advanced cancer);\n3. Unable to participate in sports training or have drug contraindications;\n4. Current alcohol, drug abuse, drug use or suicidal intent;\n5. Patients who were receiving other doses of eligible drugs and other antidepressants were excluded from the trial;\n6. Myocardial infarction \\\u003C2 weeks or unstable angina attack period;\n7. Severe and uncontrolled arrhythmia;\n8. Acute heart failure stage;\n9. Severe and symptomatic obstruction of the outflow tract;\n10. Acute deep vein thrombosis with or without pulmonary embolism;\n11. Acute myocarditis, pericarditis or endocarditis;\n12. Acute aortic dissection;\n13. Intracardiac thrombus with high risk of embolism;\n14. Massive pericardial effusion;\n15. Those who fail to exercise adequately or refuse to sign informed consent.","70 Years",{"count":362,"type":21},106,[24],"Psycho-Cardiological Disease studies the complex links between the cardiovascular system and emotions. The two diseases are now the focus of public health organizations, forming a vicious circle of mutual influence. Anxiety and depressive symptoms are three to four times more common in patients with cardiovascular disease than in the general population, and about 15 to 18 percent of patients with coronary heart disease also have major depression, while 25 to 30 percent show significant depressive symptoms. At least 20% of patients with chronic heart failure have some degree of depression. In addition, the probability of cardiovascular events is 2.5 times higher in patients with two hearts, the risk of recurrence of cardiovascular events is heightened, and is strongly associated with higher mortality. At present, the common treatment methods show different advantages and disadvantages, for example, Antipsychotics treatment is a common means of depression\u002Fanxiety symptoms, with rapid onset, significant efficacy, wide application and other advantages. However, medications often struggle to fully relieve symptoms, have a high recurrence rate, and can have side effects. Psychotherapy as a traditional intervention method for mental disorders. Its advantages are long-lasting efficacy and no Antipsychotics dependence, but the effect is slower, and patients need to invest more time, energy and financial resources, and the psychological burden is also heavier. In recent years, exercise therapy, as a safe intervention without significant side effects, has been gradually included in a number of international clinical guidelines, and is regarded as the first-line recommended treatment for mild to moderate depression. Research has shown that exercise can effectively relieve anxiety and depression symptoms through a variety of mechanisms, such as lowering cortisol levels, regulating autonomic nervous system function, and reducing stress responses. A study of aerobic exercise in patients with Psycho-Cardiological Disease showed that a 16-week exercise intervention significantly reduced patients' depression scores and significantly improved mood and cognitive function. In addition, it has been validated in multiple studies that exercise can significantly reduce anxiety and depression symptoms by enhancing neuroplasticity, promoting neurogenesis and synaptic remodeling, improving cognitive and emotional regulation. These findings provide a strong theoretical and practical basis for the application of exercise therapy in the comprehensive management of Psycho-Cardiological Disease. The above studies provide important theoretical support for the treatment of biheart disease with exercise, but most studies focus on scale scores, biomarkers, and changes in social behavior. It is well known that antidepressant or anti-anxiety drugs can have many side effects due to their dosage, duration and long-term use, which in turn poses a potential risk to the overall health and quality of life of patients. Therefore, it is of significant clinical significance and research value to explore whether exercise as an adjunct therapy can effectively reduce the use of Antipsychotics and shorten the withdrawal period. This will not only help optimize personalized treatment plans, provide scientific basis for clinical decision-making, but also promote the development of Psycho-Cardiological Disease treatment to the direction of precision and integration.",[366,29],"Cardiovascular Diseases (CVD)","2025-06-13",{"date":369,"type":42},"2025-06-17",{"date":371,"type":42},"2025-04-22",{"date":373,"type":21},"2027-03-31",{"name":375,"class":49},"Guangdong Provincial People's Hospital",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":22,"phases":386,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":50},"100586636","phase-1-roxadustat-for-bone-and-neuropsychiatric-aspects-in-hemodialysis-patients-100586636","NCT06917950","Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","Effect of Roxadustat on Bone and Neuropsychiatric Aspects in End Stage Kidney Disease Patients on Hemodialysis","ROXA-BN-HD","Inclusion Criteria:\n\n* The age of the patient is more than 18.\n* Patients who are willing to sign informed consent.\n* Patients with ESKD on chronic hemodialysis for more than 3 months.\n\nExclusion Criteria:\n\n* Current pregnancy or lactation.\n* Patients with pre-existing malignancy.\n* patients with psychosis.\n* Known history of hematological disorders or other causes of anemia other than CKD.\n* Taking medications that may significantly affect or interact with bone metabolism such as osteo-anabolics or bone resorptives during the last 6 months.",{"count":385,"type":21},46,[387,318],"PHASE1","People with severe kidney failure who need regular hemodialysis treatment often experience several health problems. These include anemia (low red blood cell count), issues with their bone health (sometimes called mineral and bone disease), and mental health challenges like depression and anxiety. They may also have problems with their nerves and muscles.\n\nRoxadustat is a newer medicine, taken as a pill, used to treat anemia caused by kidney disease. It works differently than the standard injectable medications often used.\n\nThis study aims to investigate if Roxadustat has effects beyond treating anemia in hemodialysis patients. Specifically, researchers want to see if taking Roxadustat affects patients' bone health (measured by bone density scans and blood tests) and their psychological well-being (looking at symptoms of depression and anxiety using questionnaires). The study will also use ultrasound to look at potential changes in nerves and muscles.\n\nThe study will enroll 46 patients on hemodialysis. Patients will be randomly assigned (like flipping a coin) into two groups. One group (23 patients) will receive Roxadustat three times a week, while the other group (23 patients) will continue receiving their usual conventional treatment for anemia.\n\nAll patients will be followed for 6 months. During this time, they will have regular blood tests, bone density scans (using a technique called QCT), nerve and muscle ultrasound examinations, and will complete questionnaires about their mood.\n\nResearchers will compare the results between the two groups to understand the effects of Roxadustat on bone, mood, anxiety, and neuromuscular aspects in patients undergoing hemodialysis",[390,391,29],"Kidney Failure,Chronic","Anemia in End Stage Renal Disease",[393,394,395,396,397,398,399],"Roxadustat","Hemodialysis","Renal Anemia","Bone Mineral Density (BMD)","Quantitative Computed Tomography (QCT)","Neuropsychiatric","Musculoskeletal Ultrasound (MSK-US)","2025-05-07",{"date":402,"type":42},"2025-05-11",{"date":404,"type":42},"2025-04-15",{"date":406,"type":21},"2025-11-01",{"name":408,"class":49},"Mansoura University",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":416,"maxAge":59,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100584859","phase-2-hybrid-type-2-implementation-effectiveness-trial-of-a-third-wave-virtual-reality-treatment-for-youth-depressionanxiety-100584859","NCT06894836","Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression\u002FAnxiety","Hybrid Type 2 Implementation-Effectiveness Trial of a Third Wave Virtual Reality Treatment for Youth Depression and Anxiety","There are three populations recruited for this trial:\n\nINCLUSION CRITERIA\n\nYoung people\n\n1. Aged between 12-25 years (inclusive)\n2. Current client of a participating youth mental health service\n3. Seeking or receiving treatment for depression and\u002For anxiety\n4. Sufficient command of the English language\n\nClinicians Employed at a participating youth mental health service and involved in the delivery of psychological treatment of young people presenting with depression and anxiety\n\nService staff Work within a participating youth mental health service in a leadership (team lead or service manager) or administrative role.\n\nEXCLUSION CRITERIA:\n\nYoung people\n\n1. Moderate or severe audio or visual condition precluding engagement with the VR equipment (assessed on a case-by-case basis)\n2. Counter indication based on clinical judgement e.g., active suicidal risk or intellectual disability.\n\nClinicians Unable to commit to delivering the MIND intervention (5 sessions over 10-12 weeks).\n\nService staff Nil","12 Years",{"count":418,"type":21},75,[318],"This research will evaluate a new virtual reality (VR) intervention to support youth with depression and anxiety. While VR has shown promise for adult mental health, little is known about its use in youth or routine clinical care. The VR intervention is based on Acceptance and Commitment Therapy (ACT) and immerses young people in fun, engaging environments to teach practical coping skills for managing distress. Clinicians within youth mental health services will use the VR intervention within their routine treatment of young people. The study will evaluate both the preliminary effectiveness of the VR intervention for improving youth mental health, as well as real-world implementation outcomes to understand how it can be successfully adopted in clinical settings. The trial will use a single-group, pre-post design, with treating clinicians delivering the intervention to up to 75 young people seeking treatment for depression and anxiety over a 12-week period. Assessments will be conducted at baseline, immediately after the intervention (12 weeks), and four weeks post-intervention (16 weeks).",[29],[423,424,425,232,28,426],"Virtual reality","Acceptance and commitment therapy","Youth mental health","Psychological intervention","2025-03-30",{"date":429,"type":42},"2025-04-03",{"date":431,"type":21},"2025-04-01",{"date":433,"type":21},"2026-10-01",{"name":435,"class":49},"Orygen",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":93,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":444,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":459,"locationsCount":50},"100584689","efct-vs-bct-for-depression-and-anxiety-in-married-couples-100584689","NCT06892613","EFCT vs. BCT for Depression and Anxiety in Married Couples","A Comparison of the Effectiveness of Emotion-Focused Couples Therapy and Behavioral Couples Therapy in Reducing Depression and Anxiety Symptoms in Married Couples","EFCT-BCT","Inclusion Criteria:\n\n* Married couples aged between 18 and 65 years\n* Married for at least one year\n* No current psychiatric diagnosis or history of psychiatric treatment\n* Not receiving any form of psychological therapy at the time of recruitment\n* Ability to provide informed consent\n* Willingness to participate in all therapy sessions and assessments\n\nExclusion Criteria:\n\n* Current or past psychiatric diagnosis (excluding mild transient conditions)\n* Ongoing psychological therapy or psychiatric treatment\n* Severe mental health disorders (e.g., schizophrenia, bipolar disorder), Substance abuse or dependency\n* Severe medical conditions that may interfere with participation\n* Refusal to participate in follow-up assessments",{"count":445,"type":21},150,[24],"This study compares the effectiveness of Emotion-Focused Couples Therapy (EFCT) and Behavioral Couples Therapy (BCT) in reducing depression and anxiety symptoms in married couples. A total of 150 married couples aged 18-65 will be screened, and 60 couples with high depression and anxiety levels will be selected. These couples will be randomly assigned to one of three groups: EFCT, BCT, or a control group. Therapy sessions will be conducted weekly for 12 weeks, with assessments before therapy, after the 6th and 12th sessions, and at a 3-month follow-up. The study aims to determine which therapy is more effective in improving mental health outcomes in couples.",[29,28],[232,28,450,451,295,452,453],"Emotion-Focused Couples Therapy","Behavioral Couples Therapy","Psychotherapy","Marital Counseling","2025-03-21",{"date":456,"type":42},"2025-03-25",{"date":238,"type":42},{"date":344,"type":21},{"name":460,"class":49},"Beykoz University"]